ABPI 1, NICE 0: industry shifts pricing influence away from UK HTA body
This article was originally published in Scrip
The UK pharma industry association, the ABPI, has won a victory over NICE, the health technology appraisal institute for England and Wales, in the ongoing negotiations over value-based pricing. Currently, NICE sets the cost-effectiveness thresholds that influence UK drug pricing and the role of NICE itself was outside the ABPI’s sphere of influence. But the ABPI's chief executive Stephen Whitehead told Scrip that those thresholds are now part of the negotiations rather than being outside them.
You may also be interested in...
Pharmaceutical industry groups say the European Commission’s Pharmaceutical Strategy Roadmap lacks detail on delivering a faster regulatory process and encouraging competitiveness.
The Australian Therapeutic Goods Administration is consulting on a draft standard for data matrix codes on the labels of certain medicines.
The European Medicines Agency received more requests for scientific advice in 2019 than it did in 2018. Meanwhile, requests for advice in other areas has fallen.